News und Analysen
Evolva and LEHVOSS sign agreement for distribution of Veri-teTM Resveratrol in over a dozen European countries
Evolva and LEHVOSS sign agreement for distribution of Veri-teTM Resveratrol in over a dozen European countries
Evolva and Nice & Green agree on improvements to financing agreement
Evolva and Nice & Green agree on improvements to financing agreement
Evolva receives approval for Veri-teTM Resveratrol in Thailand
Evolva receives approval for Veri-teTM Resveratrol in Thailand
Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023
Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023
Evolva with good business momentum and significant progress in profitability in 1H 2023, despite major financing challenges
Evolva with good business momentum and significant progress in profitability in 1H 2023, despite major financing challenges
Kuros Biosciences Reports Results for First Half 2023
Kuros Biosciences Reports Results for First Half 2023
Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year
Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year
Evolva receives approval for Veri-teTM Resveratrol in Taiwan
Evolva receives approval for Veri-teTM Resveratrol in Taiwan
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
Evolva Holding SA: Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives
Evolva Holding SA: Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Annual General Meeting of Kuros Biosciences approves all resolutions
Annual General Meeting of Kuros Biosciences approves all resolutions
Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026
Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
Evolva publishes timeline of the Reverse Stock Split
Evolva publishes timeline of the Reverse Stock Split
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
Evolva publishes agenda for 2023 Annual General Meeting
Evolva publishes agenda for 2023 Annual General Meeting
Kuros Biosciences reports results for the full year 2022
Kuros Biosciences reports results for the full year 2022
Evolva delivers accelerated revenue growth of 57% in 2022 and substantially improved profitability profile
Evolva delivers accelerated revenue growth of 57% in 2022 and substantially improved profitability profile
Evolva partners with Grace Breeding to replace chemical fertilizers with nature-based alternative
Evolva partners with Grace Breeding to replace chemical fertilizers with nature-based alternative
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
Kuros Biosciences Announces Changes to Executive Management Team
Kuros Biosciences Announces Changes to Executive Management Team
Evolva delivers strong results with 57% revenue growth and increasing margins
Evolva delivers strong results with 57% revenue growth and increasing margins